What Is Post-Marketing Surveillance in Pharmacovigilance? – safety and pharmacovigilance Understanding Post-Marketing Surveillance in Pharmacovigilance Post-Marketing Surveillance (PMS) in pharmacovigilance is crucial for maintaining drug safety and efficacy after a product has entered the market. This article serves as a comprehensive manual for professionals involved in drug safety and pharmacovigilance, outlining regulatory requirements and best practices in various global regions including the US, EU, and India. How to Implement an Effective Post-Marketing Surveillance Strategy To establish a robust PMS framework, companies must design a strategy that complies with local regulations, addresses market-specific challenges, and fulfills the expectations of both regulatory…

FDA’s Post-Marketing Study and Reporting Requirements – pharmacovigilance safety FDA’s Post-Marketing Study and Reporting Requirements How to Understand the Regulatory Framework for Post-Marketing Studies Post-Marketing Studies (PMS) play a vital role in ensuring the safety and efficacy of medicinal products following their approval for market use. The FDA, EMA, and other regulatory agencies impose specific guidelines to govern these studies, primarily under the principles of pharmacovigilance safety. Understanding these frameworks is crucial for regulatory affairs professionals in navigating post-marketing obligations. The FDA regulates post-marketing studies under the authority of the Federal Food, Drug, and Cosmetic Act. They can mandate post-marketing…

EMA’s Risk-Based Post-Authorization Safety Studies (PASS) – drug safety and pharmacovigilance EMA’s Risk-Based Post-Authorization Safety Studies (PASS) – drug safety and pharmacovigilance Post-authorization safety studies (PASS) are a fundamental aspect of the drug safety and pharmacovigilance frameworks established by regulatory agencies such as the European Medicines Agency (EMA). This article provides a comprehensive guide on how to navigate the complexities of PASS, including compliance expectations, study design, and the responsibilities of stakeholders involved in these studies. How to Understand the Concept and Importance of Risk-Based PASS Risk-Based Post-Authorization Safety Studies (PASS) serve to evaluate the safety profile of a drug…

CDSCO’s Post-Marketing Safety Monitoring Guidelines – drug safety pharmacovigilance CDSCO’s Post-Marketing Safety Monitoring Guidelines: A Comprehensive Regulatory Manual The Central Drugs Standard Control Organization (CDSCO) in India has developed specific guidelines aimed at ensuring the safety and efficacy of pharmaceutical products post-marketing. This article delves into the post-marketing safety monitoring guidelines provided by the CDSCO, focusing on drug safety pharmacovigilance. We will cover compliance expectations, processes, and actionable guidance for professionals involved in pharmacovigilance and medical writing in clinical research. How to Understand CDSCO’s Post-Marketing Safety Monitoring Guidelines Understanding CDSCO’s guidelines requires a thorough grasp of both its foundational principles…

Japan’s PMS Requirements Under PMDA for Drugs and Devices – medical writing in clinical research Japan’s PMS Requirements Under PMDA for Drugs and Devices Post-Marketing Surveillance (PMS) represents a crucial stage in the drug and medical device lifecycle, ensuring safety and efficacy through ongoing monitoring. In Japan, the Pharmaceuticals and Medical Devices Agency (PMDA) oversees PMS obligations, making compliance imperative for pharmaceutical companies operating within or targeting the Japanese market. This article provides a comprehensive guide on how to align with PMS requirements as outlined by the PMDA, providing actionable insight into medical writing in clinical research. How to Understand…

PMS Obligations for Biologics and Vaccines Globally – pharmaceutical regulatory agencies PMS Obligations for Biologics and Vaccines Globally Understanding the post-marketing surveillance obligations for biologics and vaccines is essential for compliance with various pharmaceutical regulatory agencies worldwide. These obligations often differ by region and regulatory body. This article will provide a comprehensive, how-to guide for professionals engaged in these processes, focusing on aligning with the FDA, EMA, MHRA, and other relevant organizations. How to Understand Global PMS Obligations for Biologics and Vaccines Post-marketing surveillance (PMS) is a crucial aspect of drug safety and risk management. After a drug or biologic…

Differences in PMS Reporting Timelines Across Regions – regulatory agencies for pharmaceutical Differences in PMS Reporting Timelines Across Regions Post-Marketing Surveillance (PMS) is a critical aspect of ensuring the safety and efficacy of pharmaceutical products after they have been approved for market use. Understanding the key differences in the PMS reporting timelines across various regions is essential for compliance with regulatory agencies for pharmaceutical products. This comprehensive manual aims to provide actionable guidance on navigating the PMS landscape, focusing on the expectations set forth by major regulatory bodies such as the FDA, EMA, MHRA, and others. How to Understand the…

How PMS Data Influences Labeling and Risk Minimization – drug regulatory agencies How PMS Data Influences Labeling and Risk Minimization – drug regulatory agencies How to Understand the Role of PMS Data in Drug Regulation Post-Marketing Surveillance (PMS) plays a critical role in the lifecycle management of pharmaceutical products. It involves the collection and analysis of data on the safety and effectiveness of a drug after it has been released to the market. Regulatory agencies such as the FDA, EMA, MHRA, and others, utilize this data to ensure ongoing compliance with safety standards. Understanding how PMS data influences decisions made…

Periodic Benefit-Risk Evaluation in Post-Marketing Phase – pharmaceutical regulatory agencies Periodic Benefit-Risk Evaluation in Post-Marketing Phase: A Guide for Pharmaceutical Regulatory Agencies The post-marketing phase of pharmaceutical products is crucial for assessing their long-term safety and efficacy. One of the pivotal components of this phase is the Periodic Benefit-Risk Evaluation Report (PBRER). This guide offers an extensive overview of how to effectively conduct a PBRER in alignment with the requirements set forth by various global pharmaceutical regulatory agencies. Moreover, it addresses the compliance expectations and best practices needed for effective pharmacovigilance and clinical safety. How to Understand the Regulatory Framework…

Tools and Techniques for Effective PMS Data Collection – regulatory agencies for pharmaceutical Tools and Techniques for Effective PMS Data Collection How to Understand Post-Marketing Surveillance Requirements by Regulatory Agencies Post-Marketing Surveillance (PMS) is a critical component in maintaining the safety of medicinal products once they are on the market. Regulatory agencies for pharmaceutical products, such as the FDA, EMA, MHRA, Health Canada, and PMDA, impose stringent requirements to ensure drugs remain safe for public use. Understanding these requirements is essential for pharmaceutical companies to comply effectively and to ensure patient safety. Each regulatory agency offers guidelines on PMS data…